Nanosensors and Nanomodulators in Cancer Therapies
A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Nanobiotechnology and Biofabrication".
Deadline for manuscript submissions: closed (1 December 2024) | Viewed by 6692
Special Issue Editor
Interests: nanosensing; plasmonics; nanopores; cancer immunotherapy; protein-protein interactions; nanoparticle characterization
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Diagnosing and training cancer with nanotechnology-based approaches is tremendously promising, as it can result in lower side effects and personalized interventions that lead to long-term disease remission. However, the effectiveness of nanotechnology-based approaches has not been consistent. A key variability driver in therapeutic responses is a current lack of technologies to design and implement personalized treatments.
The intersection of nanoscience with cancer therapies opens a world of new opportunities for personalized interventions. An incomplete list of such opportunities includes (1) ultrasensitive nanosensors detecting minute amounts of a biomarker, which could, in turn, enable the detection of multiple biomarkers out of a limited biopsy sample; (2) nanoparticles helping make a tumor visible to the physician, thus enhancing the possibility of successful surgical resection; (3) novel nanomaterials implanted in vivo to sequester biomarkers and/or cancer-relevant ligands to guide the synthesis of personalized treatments; (4) nanoparticles engineered in various architectures to help visualize therapy response or serve as patient-specific treatments, e.g., adeno-associated viruses, lentiviruses, lipid nanoparticles, and extracellular vesicles.
The current Special Issue emphasizes research at the intersection of nanosensing (devices) and nanomodulation (nanoparticles) for all aspects of cancer therapy, including diagnostic biomarker detection, validation of tumor targeting, and therapeutic response monitoring. It is highly encouraged that submitted manuscripts include a candid discussion of how the proposed technologies or methods could address current weaknesses in established interventions and describe the critical future milestones that would need to be attained to enable their successful translation to the clinic.
Prof. Dr. Georgios Alexandrakis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cellular or in vivo imaging of nanoparticle-guided cancer immunotherapy responses
- sorting or nano-sieving of ligands or receptors driving immune responses to cancer
- label-guided or label-free biomarker imaging of immunotherapy response
- ultra-sensitive nanosensing of immune-actionable cancer biomarkers in liquid samples
- new nanomaterials or nanoparticles to modulate the immune system's response to cancer
- cancer vaccines and new check-point inhibitor development and testing
- liposomes or other soft nanoparticles to modulate immune responses to cancer
- nanoparticle-mediated gene delivery or editing for immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
